Form 4: Century Therapeutics Director Joseph Jimenez Granted 44,000 Stock Options

Century Therapeutics, Inc. Director Joseph Jimenez was granted 44,000 stock options with an exercise price of $0.60, vesting based on continued service.

Summary

• Joseph Jimenez, a Director of Century Therapeutics, Inc. (IPSC), was granted 44,000 stock options.
• The options have an exercise price of $0.60 per share.
• The options were granted on June 12, 2025.
• The options vest on the earlier of June 12, 2026, or the next annual meeting of stockholders, contingent upon Mr. Jimenez's continued service.
• The expiration date for these stock options is June 12, 2035.
• Following this transaction, Mr. Jimenez beneficially owns 44,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it represents a standard compensation event that aligns director interests with shareholder value, without indicating any immediate negative implications for the company's operations or financial health.

Positives

• The grant of stock options aligns the interests of Director Joseph Jimenez with those of the shareholders, as the value of the options increases with the company's stock price.
• This is a standard form of executive and director compensation, indicating ongoing commitment and incentivization for key personnel.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, although this is a common aspect of equity compensation plans.

Future Outlook

The stock options granted to Director Joseph Jimenez are subject to a vesting schedule, which will occur on the earlier of June 12, 2026, or the next annual meeting of stockholders, provided he continues his service to the company through the applicable vesting date. The options have a long-term expiration date of June 12, 2035, allowing for future potential exercise.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, particularly for companies like Century Therapeutics, Inc. (IPSC), which often rely on equity-based compensation to attract and retain experienced leadership. This practice helps align the long-term interests of directors with the company's performance and shareholder value creation.

Related Party Transactions

• The grant of stock options to Joseph Jimenez, a Director of Century Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from aligned director incentives.
• Director (Joseph Jimenez): Receives equity-based compensation, incentivizing long-term performance and retention.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the next annual meeting of stockholders, subject to Joseph Jimenez's continued service.
• Upon vesting, Joseph Jimenez will have the right to exercise the options at $0.60 per share until their expiration on June 12, 2035.

Key Dates

Keywords

Century Therapeutics, IPSC, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Joseph Jimenez